Durvalumab: tested with established drugs

76 studies: they are given beside it. Page 1 of 1. Open to participants first (19), then studies with results posted, then the rest; newest registration first within each.

• A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.RecruitingNCT07877818Phase 3Report a problem
• Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung CancerRecruitingNCT07149363Phase 2Report a problem
• Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)RecruitingNCT06960577Phase 2Report a problem
• Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast CancerRecruitingNCT06954480Phase 2Report a problem
• Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extra- and Intrahepatic CholangiocarcinomaRecruitingNCT06440993Phase 2Report a problem
• Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC)RecruitingNCT06418087Phase 2Report a problem
• Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological TherapyRecruitingNCT06375915Phase 2Report a problem
• Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)RecruitingNCT06371482Phase 2Report a problem
• Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLCRecruitingNCT06223711Phase 2Report a problem
• First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine CarcinomaRecruitingNCT06070740Phase 2Report a problem
• Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence RiskRecruitingNCT05672537Phase 2Report a problem
• Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract CancerRecruitingNCT05640791Phase 2Report a problem
• Olaparib with or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based ChemotherapyRecruitingNCT05222971Phase 2Report a problem
• Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)RecruitingNCT05068232Phase 2Report a problem
• Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 TherapyRecruitingNCT04892953Phase 2Report a problem
• WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOCRecruitingNCT04644289Phase 2Report a problem
• Efficacy and Safety of CRT, Durvalumab and Surgery for SSTNot yet recruitingNCT04465968Phase 3Report a problem
• Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ TrialRecruitingNCT03907475Phase 2Report a problem
• Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell LymphomaRecruitingNCT03011814Phase 1/2Report a problem
• Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT06083454Phase 1Results postedReport a problem
• Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)CompletedNCT04449861Phase 3Results postedReport a problem
• Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)CompletedNCT04385368Phase 3Results postedReport a problem
• ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-ImmunotherapyTerminatedNCT04372927Phase 2Results postedReport a problem
• Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung CancerTerminatedNCT04364048Phase 2Results postedReport a problem
• Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder CancerTerminatedNCT03912818Phase 2Results postedReport a problem
• Aromatase Inhibitor and Durvalumab in Postmenopausal Breast CancerTerminatedNCT03874325Phase 2Results postedReport a problem
• Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)CompletedNCT03830866Phase 3Results postedReport a problem
• Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast CancerActive, not recruitingNCT03820141Phase 2Results postedReport a problem
• Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung CancerCompletedNCT03794544Phase 2Results postedReport a problem
• Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBCActive, not recruitingNCT03732677Phase 3Results postedReport a problem
• Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung CancerCompletedNCT03519971Phase 3Results postedReport a problem
• Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)CompletedNCT03167619Phase 2Results postedReport a problem
• A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)CompletedNCT03000452Phase 2Results postedReport a problem
• An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)CompletedNCT02775903Phase 2Results postedReport a problem
• A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.Active, not recruitingNCT02734004Phase 1/2Results postedReport a problem
• A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT02733042Phase 1/2Results postedReport a problem
• A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid TumorsCompletedNCT02403271Phase 1/2Results postedReport a problem
• A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory LymphomasCompletedNCT02401048Phase 1/2Results postedReport a problem
• Phase 2 Study of Durvalumab (MEDI4736) in Patients With GlioblastomaCompletedNCT02336165Phase 2Results postedReport a problem
• A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck CancerTerminatedNCT02291055Phase 1/2Results postedReport a problem
• Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)Active, not recruitingNCT05771480Phase 3Report a problem
• Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLCStatus unknownNCT05157542Phase 1Report a problem
• A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the BladderActive, not recruitingNCT05137262Phase 2Report a problem
• A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLCStatus unknownNCT04982549Phase 2Report a problem
• A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung CancerTerminatedNCT04870112Phase 1Report a problem
• Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLCTerminatedNCT04765709Phase 2Report a problem
• Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics ModelsStatus unknownNCT04646837Phase 1/2Report a problem
• Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction CancerActive, not recruitingNCT04592913Phase 3Report a problem
• Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell CarcinomaCompletedNCT04568200Phase 2Report a problem
• Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCCActive, not recruitingNCT04550260Phase 3Report a problem
• Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT04447612Phase 2Report a problem
• Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal MetastasisStatus unknownNCT04356222Phase 4Report a problem
• Neoadjuvant Gemcitabine Plus Cisplatin with or Without Durvalumab in Resectable Biliary Tract CancerActive, not recruitingNCT04308174Phase 2Report a problem
• Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung CancerWithdrawnNCT04262869Phase 2Report a problem
• Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)Status unknownNCT04255836Phase 2Report a problem
• Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study GroupActive, not recruitingNCT04230759Phase 2Report a problem
• CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)Active, not recruitingNCT04116047Phase 3Report a problem
• Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung CancerActive, not recruitingNCT04092283Phase 3Report a problem
• A Trial Evaluating Stereotactic Radiotherapy Plus Durvalumab Continuation for Patients With NSCLC Metachronous Oligometastatic Disease Under Durvalumab Consolidation Following ChemoradiationCompletedNCT03955198Phase 2Report a problem
• A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung CancerActive, not recruitingNCT03800134Phase 3Report a problem
• Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736)Active, not recruitingNCT03795207Phase 2Report a problem
• Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcerCompletedNCT03777813Phase 2Report a problem
• A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)CompletedNCT03773666Phase 1Report a problem
• Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCCWithdrawnNCT03673735Phase 3Report a problem
• Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder CancerActive, not recruitingNCT03528694Phase 3Report a problem
• Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.CompletedNCT03356860Phase 1/2Report a problem
• Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell LymphomaStatus unknownNCT03054532Phase 2Report a problem
• Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell CarcinomaTerminatedNCT02997332Phase 1Report a problem
• Study of Azacitidine and Durvalumab in Advanced Solid TumorsCompletedNCT02811497Phase 2Report a problem
• Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast CancerCompletedNCT02802098Early Phase 1Report a problem
• Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)Active, not recruitingNCT02726997Phase 1/2Report a problem
• Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving TrastuzumabCompletedNCT02649686Phase 1Report a problem
• Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer PatientsCompletedNCT02628132Phase 1/2Report a problem
• A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT02616640Phase 1Report a problem
• A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic MalignanciesCompletedNCT02572687Phase 1Report a problem
• MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).CompletedNCT02088112Phase 1Report a problem

← Durvalumab